The Next Hot Sector is Upon us and You Will Never Guess What It is
April 16 2020 - 8:00AM
InvestorsHub NewsWire
The Next Hot Sector is Upon us and
You Will Never Guess What It is
New York, NY -- April 16, 2020 --
InvestorsHub NewsWire -- via Traders News
Source -- Traders News Source, a leading
independent equity research and corporate access firm focused on
small cap growth companies’ issues their latest research “The Next
Hot Sector”
SCWorx Corp. (NASDAQ:
WORX) has received a committed purchase order from
Rethink My Healthcare, a U.S.-based virtual healthcare network, for
2 million coronavirus testing kits. SCWorx will supply Rethink My
Healthcare with IgM/IgG Rapid Detection Kits. SCWorx said it
expects to receive the first 2 million rapid detection kits within
approximately two weeks. The company said the agreement includes a
“provision" for additional weekly orders of 2 million units for 23
weeks, valued at $35 million per week. The IgM/IgG Rapid Test is an
in-vitro diagnostic test solely for the qualitative determination
of Covid-19’s IgM and IgG antibodies in human whole blood, serum,
plasma and fingertip blood. The company also stated that additional
purchase orders currently under negotiation with certain other
parties could further increase the U.S. supply of these important
tests in the near term.
On April 14th, Premier
Biomedical Inc. (OTC:
BIEI) announced the filing of a provisional patent
application, "Method for Treating Covid-19 Inflammatory Cytokine
Storm for the Reduction of Morbidity and Mortality in Covid-19
Patients," The provisional patent application involves the targeted
removal of disease-specific antigens via an extracorporeal process.
These antigens have been identified in the medical literature to be
the pathophysiologic basis for the overwhelming production of lung
edema and mucus in Covid-19 patients. The core of this technology
is the selective removal of blood-borne antigens associated with
the ability of Covid-19 to replicate and is consistent with their
patented core technology. The company states it has proven in the
laboratory that they can remove specific selected blood-borne
antigens from a similar mixture using their patented
technology.
Ever wish you were aware of a hot
new sector before it experiences explosive growth? Hot new sector
in its infancy gaining traction now READ MORE
Copy and paste to browser may be
required https://www.industrynews.tips/
Predictive Technology
Group, Inc. (OTC:
PRED) harnesses predictive gene-based analytics to
develop genetic and molecular diagnostic tests, as well as
companion therapeutics. The company is involved in a collaboration
with Atrin Pharmaceuticals to utilize next-generation genomics
capabilities to improve predictive selection of clinical study
patients most likely to respond and least likely to experience side
effects from treatment with Atrin’s DDR drug candidates. Atrin and
Predictive have been jointly developing proprietary approaches to
better identify patients with specific mutations that drive cancer
tumor growth, regardless of tumor type, and who are most likely to
clinically respond to synthetically lethal anti-cancer
therapies.
CytoDyn Inc. (OTCQB:
CYDY) reported recently it had filed an
Investigational New Drug (IND) application to launch a Phase 2
trial in the U.S. with leronlimab (PRO 140) in patients infected
with the COVID-19 coronavirus. Deaths caused by COVID-19 are
mostly a result of acute respiratory distress syndrome (ARDS), as
the virus in human lungs causes an influx of macrophage and immune
cells and the cytokines released result in even more influx of
immune cells and inflammation. As an immunomodulator, leronlimab
could disrupt this cycle and reduce ARDS-related
mortality.
Ever wish you were aware of a hot
new sector before it experiences explosive growth? Hot new sector
in its infancy gaining traction now READ
MORE
Copy and paste to browser may be
required – https://www.industrynews.tips/
Disclosure
Traders News Source LLC (TNS)
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
small and micro-cap equity markets. TNS has two distinct and
independent departments. One department produces non-sponsored
analyst certified content generally in the form of press releases,
articles and reports covering equities listed on NYSE, NASDAQ and
OTC exchanges. The other produces sponsored content (in most cases
not reviewed by a registered analyst), which typically consists of
compensated investment newsletters, articles and reports covering
listed stocks and micro-caps. Such sponsored content is outside the
scope of procedures detailed below.
PRESS RELEASE
PROCEDURES
The sponsored and non-sponsored
content contained herein has been prepared by a writer (the
"Author") and is fact checked and reviewed by a third-party
research service company (the "Reviewer") represented by a
chartered financial analyst, for further information on analyst
credentials, please email editor@tradersnewssource.com.
TNS LLC provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written, and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author per
the procedures outlined by TNS. TNS is not entitled to veto or
interfere in the application of such procedures by the third-party
research service company to the articles, documents, or reports.
Unless otherwise noted, any content outside of this document has no
association with the Author or the Reviewer in any
way.
NO WARRANTY
TNS, the Author, and the Reviewer
are not responsible for any error which may be occasioned at the
time of printing of this document or any error, mistake, or
shortcoming. No liability is accepted whatsoever for any direct,
indirect, or consequential loss arising from the use of this
document. TNS, the Author, and the Reviewer expressly disclaim any
fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Additionally, TNS, the Author, and
the Reviewer do not (1) guarantee the accuracy, timeliness,
completeness, or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as
an offering, recommendation, or a solicitation of an offer to buy
or sell the securities mentioned or discussed and is to be used for
informational purposes only. Please read all associated disclosures
and disclaimers in full before investing. Neither TNS nor any party
affiliated with us is a registered investment adviser or
broker-dealer with any agency or in any jurisdiction whatsoever. To
read our report(s), disclosures, or for more information, visit
http://www.tradersnewssource.com.
For any questions, inquiries, or
comments reach out to us directly. If you're a company we are
covering and wish to no longer be featured on our coverage list,
contact us via email at: editor@tradersnewssource.com
CFA® and Chartered Financial
Analyst® are registered trademarks owned by CFA
Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News
Source
Premier Biomedical (PK) (USOTC:BIEI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Premier Biomedical (PK) (USOTC:BIEI)
Historical Stock Chart
From Aug 2023 to Aug 2024